Acetylcholine receptors and myasthenia

Muscle and Nerve

Volumn 23, Issue 4, 2000, Pages 453-477

  Lindstrom, Jon M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acetylcholine receptor; Animal model; Autoimmune disease; Experimental autoimmune myasthenia gravis; Myasthenia gravis

Indexed keywords

AZATHIOPRINE; CHOLINERGIC RECEPTOR; CHOLINESTERASE INHIBITOR; PREDNISONE; RECEPTOR SUBUNIT;

ACETYLCHOLINE RELEASE; ANIMAL CELL; ANIMAL TISSUE; BINDING SITE; DISEASE ASSOCIATION; HISTOPATHOLOGY; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; PROTEIN STRUCTURE; RECEPTOR DENSITY; REVIEW; TORPEDO;

ANIMALS; ANTIBODY FORMATION; AUTOANTIBODIES; HUMANS; MUSCLE, SKELETAL; MUTATION; MYASTHENIA GRAVIS; NEURONS; RECEPTORS, CHOLINERGIC;

EID: 0034065330     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4598(200004)23:4<453::AID-MUS3>3.0.CO;2-O     Document Type: Review

References (301)

1. Alkondon M, Pereira E, Barbosa C, Albuquerque E. Neuronal nicotinic acetylcholine receptor activation modulates γ-aminobutyric acid release from CAI neurons of rat hippocampal slices. J Pharmacol Exp Ther 1997;283:1396-1411.
2. Alkondon M, Pereira E, Eisenberg H, Albuquerque E. Choline and selective antagonists identify two subtypes of nicotinic acetylcholine receptors that modulate GABA release from CAI interneurons in rat hippocampal slices. J Neurosci 1999;19:2693-2705.
3. Anand R, Bason L, Saedi M, Gerzanich V, Peng X, Lindstrom J. Reporter epitopes: a novel approach to examine transmembrane topology of integral membrane proteins applied to the α1 subunit of the nicotinic acetylcholine receptor. Biochemistry 1993;32:9975-9984.
4. Anand R, Conroy WG, Schoepfer R, Whiting P, Lindstrom J. Chicken neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes have a pentameric quaternary structure. J Biol Chem 1991;266:11192-11198.
5. Appel S, Anwyl R, McAdams M, Elias S. Accelerated degradation of acetylcholine receptor from cultured rat myotubes with myasthenia gravis sera and globulins. Proc Natl Acad Sci USA 1977;74:2130-2134.
6. Araga S, Galin F, Kishimoto M, Adachi A, Blalock J. Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptor. J Immunol 1996;157:386-392.
7. Arneric S, Brioni J, editors. Neuronal nicotinic receptors: pharmacology and therapeutic opportunities. New York: Wiley-Liss; 1999.
8. Asher O, Kues W, Witzemann V, Tzartos S, Fuchs S, Souroujon M. Increased gene expression of acetylcholine receptor and myogenic factors in passively transferred experimental autoimmune myasthenia gravis. J Immunol 1993;151: 6442-6450.
9. Atassi M, Ruan KH, Jinnai K, Oshima M, Ashizawa T. Epitope-specific suppression of antibody response in experimental autoimmune myasthenia gravis by a monomethoxypolyethylene glycol conjugate of a myasthenogenic synthetic peptide. Proc Natl Acad Sci USA 1992;89:5852-5856.
10. Bachmaier K, Neu N, de la Maza L, Pal S, Hessel A, Pennenger J. Chlamydia infections and heart disease linked through antigenic mimicry. Science 1999;283:1335-1339.
11. Baggi F, Andreetta F, Antozzi C, Simoncini O, Gonfalonieri P, Labeit S, Cornelio F, Montegazza P. Anti-titin and anti-ryanodine receptor antibodies in myasthenia gravis patients with thymoma. Ann NY Acad Sci 1998;841:538-541.
12. Bai XF, Li HL, Shi HQ, Xiao BG, Van Der Meide P, Link H. Complexities of applying nasal tolerance induction as a therapy for ongoing relapsing experimental autoimmune encephalomyelitis (EAE) in DA rats. Clin Exp Immunol 1998;111:205-210.
13. Balass M, Heldman Y, Cahilly S, Givol D, Katchoski-Katzir E, Fuchs S. Identification of a hexapeptide that mimics a conformation-dependent binding site of acetylcholine receptor by use of a phage-epitope library. Proc Natl Acad Sci USA 1993;90:10638-10642.
14. Barchan D, Asher O, Tzartos S, Fuchs S, Souroujon M. Modulation of the anti-acetylcholine receptor response and experimental autoimmune myasthenia gravis by recombinant fragments of the acetylcholine receptor. Eur J Immunol 1998;28:616-624.
15. Barchan D, Sourojon M, Im S-H, Antozzi C, Fuchs S. Antigen specific modulation of experimental myasthenia gravis: nasal tolerization with recombinant fragments of the human acetylcholine receptor a subunit. Proc Natl Acad Sci USA 1999; 96:8086-8091.
16. Bargman C. Neurobiology of the Caenorhabditis elegans genome. Science 1998;282:2028-2033.
17. Barinaga M. Antibodies linked to rare epilepsy. Science 1994;268:362-363.
18. Bartfeld D, Fuchs S. Specific immunosuppression of experimental autoimmune myasthenia gravis by denatured acetylcholine receptor. Proc Natl Acad Sci USA 1978;75: 4006-4010.
19. Beeson D, Jacobson L, Newsom-Davis J, Vincent A. A transfected human muscle cell line expressing the adult subtype of the human muscle acetylcholine receptor for diagnostic assays in myasthenia gravis. Neurology 1996;47:1552-1555.
20. Beeson D, Morris A, Vincent A, Newsom-Davis J. The human muscle nicotinic acetylcholine receptor a subunit exists as two isoforms: a novel exon. EMBO J 1990;9:2101-2106.
21. Beeson D, Pond A, Corlett L, Curnow J, Hill M, Jacobson L, MacLennan C, Meager A, Moody A-M, Moss P, Naguekar N, Newsom-Davis J, Pantic N, Roxanis I, Spack E, Vincent A, Wilcox N. Thymus, thymoma, and specific T cells in myasthenia gravis. Ann NY Acad Sci 1998;841:371-387.
22. + cells. J Immunol 1993;151:1025-1038.
23. + cell sensitized to nicotinic acetylcholine receptor. J Immunol 1991;147:1484-1491.
24. Benowitz N. Pharmacology of nicotine: addiction and therapeutics. Ann Rev Pharmacol Toxicol 1996;36:597-613.
25. Berger F, Gage F, Vijayaraghavan S. Nicotinic receptor-induced apoptotic cell death of hippocampal progenitor cells. J Neurosci 1998;18:6871-6881.
26. Bertrand D, Devillers-Thiery A, Revah F, Galzi JL, Hussy N, Mulle C, Bertrand S, Ballivet M, Changeux JP. Unconventional pharmacology of a neuronal nicotinic receptor mutated in the channel domain. Proc Natl Acad Sci USA 1992; 89:1261-1265.
27. Beroukhim R, Unwin N. Three-dimensional location of the main immunogenic region of the acetylcholine receptor. Neuron 1995;15:323-331.
28. Bevan S, Heinemann S, Lennon V, Lindstrom J. Reduced muscle acetylcholine sensitivity in rats immunized with acetylcholine receptor. Nature 1976;260:438-439.
29. Bond A, Corlett L, Curnow S, Spack E, Willcox N, Newsom-Davis J. Diverse patterns of unresponsiveness in an acetylcholine receptor-specific T-cell clone from a myasthenia gravis patient after engaging the T-cell receptor with three different ligands. J Neuroimmunol 1998;82:182-190.
30. Boulter J, Evans K, Goldman D, Martin G, Treco D, Heinemaun S, Patrick J. Isolation of a cDNA clone coding for a possible neural nicotinic acetylcholine receptor a subunit. Nature 1986;319:368-374.
31. Broide R, Orr-Urtreger A, Kasten M, Dang H, Dani J, Beaudel A, Patrick J. Mice heterozygous for the α7 L250T nicotinic acetylcholine receptor mutation show a partial gain of function for this receptor. Neurosci Soc Mtg Abstr 1999;75:1.
32. Bufler J, Pitz R, Czep M, Wick M, Franke C. Purified IgG from seropositive and seronegative patients with myasthenia gravis reversibly blocks currents through nicotinic acetylcholine receptor channels. Ann Neurol 1998;43:458-464.
33. Burges J, Vincent A, Molenaar P, Newsom-Davis J, Peers C, Wray D. Passive transfer of seronegative myasthenia gravis to mice. Muscle Nerve 1994;17:1393-1400.
34. Burges J, Wray D, Pizzeghella S, Hall Z, Vincent A. A myasthenia gravis plasma immunoglobulin reduces miniature endplate potentials at human endplates in vitro. Muscle Nerve 1990;13:407-413.
35. Carlson N, Gahring L, Twyman R, Rogers S. Identification of amino acids in the glutamate receptor, GluR3, important for antibody binding and receptor-specific activation. J Biol Chem 1997;272:11295-11301.
36. Chang K, Berg D. Nicotinic acetylcholine receptors containing α7 subunits are required for reliable synaptic transmission in situ. J Neurosci 1999;19:3701-3710.
37. Changeux JP. Functional architecture and dynamics of the nicotinic acetylcholine receptor: an allosteric ligand-gated ion channel. 1988-1989 Fidia Research Foundation Neuroscience Award Lectures. Vol. 4. New York, Raven Press; 1990. p 21-168.
38. Changeux JP, Bertrand D, Corringer PJ, Dehaene S, Edelstein S, Lena C, LeNovere N, Marubio L, Picciotto M, Zoli M. Brain nicotinic receptors: structure and regulation, role in learning and reinforcement. Brain Res Rev 1998;26: 198-216.
39. Christadoss P. Immunogenetics of experimental autoimmune myasthenia gravis. CRC Crit Rev Immunol 1989;9: 247-278.
40. Christadoss P, Lindstrom J, Melvold R, Talal N. I-A subregion mutation prevents experimental autoimmune myasthenia gravis. Immunogenetics 1985;21:33-38.
41. Cikes N, Momoi M, Williams C, Howard F, Hoagland H, Whittingham S, Lennon V. Striational autoantibodies: quantitative detection by enzyme immunoassay in myasthenia gravis, thymoma, and recipients of D-penicillamine or allogenic bone marrow. Mayo Clin Proc 1998;63:474-481.
42. Clementi F, Gotti C, Fornasari D, editors. Neuronal nicotinic receptors. Berlin: Springer; 2000.
43. Compston D, Vincent A, Newsom-Davis J, Batchelor J. Clinical, pathological, HLA antigen, and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 1981;103:579-601.
44. Conroy W, Berg D. Neurons can maintain multiple classes of nicotinic acetylcholine receptors distinguished by different subunit compositions. J Biol Chem 1995;270:4424-4431.
45. Conti-Fine B, Navaneethan D, Karachunski P, Raju R, Diethelm-Okita B, Okita D, Howard J, Wang ZY. T cell recognition of the acetylcholine receptor in myasthenia gravis. Ann NY Acad Sci 1998;841:283-308.
46. Conti-Fine B, Protti M, Bellone M, Howard J. Myasthenia gravis: the immunobiology of an autoimmune disease. Austin, TX: RG Landes; 1997.
47. Conti-Tronconi B, Tzartos S, Lindstrom J. Monoclonal antibodies as probes of acetylcholine receptor structure. II. Binding to native receptor. Biochemistry 1981;20: 2181-2191.
48. Cooper E, Couturier S, Ballivet M. Pentameric structure and subunit stoichiometry of a neuronal nicotinic acetylcholine receptor. Nature 1991;350:235-238.
49. Corey A, Richman D, Agius M, Wollman R. Refractoriness to a second episode of experimental myasthenia gravis. Correlation with AChR concentration and morphologic appearance of the post-synaptic membrane. J Immunol 1987;138: 3269-3275.
50. Corringer PJ, Bertrand S, Galzi JL, Davillers-Thiery A, Changeux JP, Bertrand D. Mutational analysis of the charge selectivity filter of the α7 nicotinic receptor. Neuron 1999;22: 831-843.
51. Couturier S, Bertrand D, Matter J, Hernandez M, Bertrand S, Millar N, Valera S, Barkas T, Ballivet M. A neuronal nicolinic acetylcholine receptor subunit α7 is developmentally regulated and forms a homomeric channel blocked by αbungarotoxin. Neuron 1990;5:847-856.
52. Croxen R, Newland C, Beeson D, Oosterhuis H, Chauplannaz G, Vincent A, Newsom-Davis J. Mutations in different functional domains of the human muscle acetylcholine receptor ot subunit in patients with the slow channel congenital myasthenic syndrome. Hum Mol Gen 1997;6: 767-774.
53. Das M, Lindstrom J. Epitope mapping of antibodies to acetylcholine receptors. Biochemistry 1991;30:2470-2477.
54. David C, McPherson P, Mundigl O, DeCamilli P. A role of amphiphysin in synaptic vesicle endocytosis suggested by its binding to dynamin in nerve terminals. Proc Natl Acad Sci USA 1996;93:331-335.
55. Dedhia V, Goluszko E, Wu B, Deng C, Christadoss P. The effect of B cell deficiency on the immune response to acetylcholine receptor and the development of experimental autoimmune myasthenia gravis. Clin Immunol Immunopathol 1998;87:266-276.
56. de Silva S, McIntosh K, Blum J, Order S, Mellits D, Drachman D. Total lymphoid irradiation and antigen-specific tolerance: future therapy for experimental myasthenia gravis? J Neuroimmunol 1990;29:93-103.
57. Dick A, Cheng Y, McKinnon A, Liversidge J, Forrester J. Nasal administration of retinal antigens suppresses the inflammatory response in experimental allergic uveoretinitis. Br J Opthalmol 1993;77:171-175.
58. + T cells from myasthenic patients and healthy subjects to biosynthetic and synthetic sequences of the nicotinic acetylcholine receptor. J Autoimmunol 1998;11:191-203.
59. Donnelly D, Mihovilovic M, Gonzalez-Ros J, Ferragut J, Richman D, Martinez-Carrion M. A noncholinergic site-directed monoclonal antibody can impair agonist-induced ion flux in Torpedo californica acetylcholine receptor. Proc Natl Acad Sci USA 1984;81:7999-8003.
60. Drachman D. Myasthenia gravis. N Engl J Med 1994;330: 1797-1810.
61. Drachman D. Immunotherapy in neuromuscular disorders: current and future strategies. Muscle Nerve 1996;19: 1239-1251.
62. Drachman D, Angus C, Adams R, Michelson J, Hoffman G. Myasthenia antibodies cross link acetylcholine receptors to accelerate degradation. N Engl J Med 1978;298:1116-1122.
63. Drachman D, Okumura S, Adams R, McIntosh K. Oral tolerance in myasthenia gravis. Ann NY Acad Sci 1996;778: 258-272.
64. Eisle JL, Bertrand S, Galzi JL, Devillers-Thiery A, Changeux JP, Bertrand D. Chimeric nicotinic-serotonergic receptor combines distinct ligand binding and channel specificities. Nature 1993;366:479-483.
65. Elgoyhen A, Johnson D, Boulter J, Vetter D, Heinemann S. α9: an acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. Cell 1994;79: 705-715.
66. Engel A. Acquired autoimmune myasthenia gravis. In: Engel A, Franzini-Armstrong C, editors. Myology, 2nd ed. New York: McGraw-Hill; 1994. p 1769-1797.
67. Engel A, editor. Myasthenia gravis and myasthenic disorders. New York: Oxford University Press; 1999.
68. Engel A, Ohno K, Bouzat C, Sine S, Griggs R. End plate acetylcholine receptor deficiency due to nonsense mutations in the ∈ subunit. Ann Neurol 1996;40:810-817.
69. Engel A, Ohno K, Milone M, Sine S. Congenital myasthenic syndromes caused by mutations in acetylcholine receptor genes. Neurology 1997;48(suppl 5):528-535.
70. Engel A, Ohno K, Milone M, Wang H-L, Nakano S, Bouzat C, Pritt J, Hutchinson D, Brengman J, Bren N, Sieb J, Sine S. New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow channel congenital myasthenic syndrome. Hum Mol Gen 1996;5:1217-1227.
71. Engel A, Ohno K, Sine S. Congenital myasthenic syndromes: recent advances. Arch Neurol 1999;56:163-167.
72. Engel A, Ohno K, Wang H-L, Milone M, Sine S. The molecular basis of congenital myasthenic syndromes: mutations in the acetylcholine receptor. Neurol Sci 1998;4:185-194.
73. Engel A, Sakakibara H, Sahashi K, Lindstrom J, Lambert E, Lennon V. Passively transferred experimental autoimmune myasthenia gravis. Neurology 1978;29:179-188.
74. Engel A, Tsujihata M, Lambert E, Lindstrom J, Lennon V. Experimental autoimmune myasthenia gravis: a sequential and quantitative study of the neuromuscular junction ultrastructure ancl electrophysiologic correlation. J Neuropathol Exp Neurol 1976;35:569-587.
75. Engel A, Tsujihata M, Lindstrom J, Lennon V. End-plate fine structure in myasthenia gravis and in experimental autoimmune myasthenia gravis. Ann NY Acad Sci 1976;274:60-79.
76. Fairclough R, Twaddle G, Gudipati E, Lin M, Richman D. Differential surface accessibility of α (187-199) in the Torpedo acetylcholine receptor α subunits. J Mol Biol 1998;282: 317-330.
77. Fairclough R, Twaddle G, Gudipati E, Stone R, Richman D, Berkwall D, Josephs R. Mapping the MAb 383C epitope to α (187-199) of the Torpedo acetylcholine receptor on the three dimensional model. J Mol Biol 1998;282:301-315.
78. Farrar J, Portolano S, Willcox N, Rapaport B, McLachlan S. Diverse Fabs specific for receptor epitopes from a myasthenia gravis combinatorial library. Int Immunol 1997;9: 1311-1318.
79. Faller G, Steininger H, Kranzlein J, Kerkau T, Hensen J, Hahn F., Kirchner T. Antigastric autoantibodies in Helicobacter pylori infection: implications of histological and clinical parameters of gastritis. Gut 1997;41:619-623.
80. Fels G, Plumer-Wilk R, Schreiber M, Maelicke A. A monoclonal antibody interfering with binding and response of the acetylcholine receptor. J Biol Chem 1986;261:15746-15754.
81. Fenster C, Berkman M, Parker, Sheffield J, Whitworth E, Quick M, Lester R. Regulation of α4β2 nicotinic receptor desensitization by calcium and protein kinase G. Mol Pharmacol 1999;55:432-443.
82. Figl A, Viseshakul N, Shafaee N, Forsayeth J, Cohen B. Two mutations linked to nocturnal frontal lobe epilepsy cause use-dependent potentiation of the nicotinic ACh response. J Physiol 1998;513:655-670.
83. Fischer U, Reinhardt S, Albuquerque E, Maelicke A. Expression of functional α7 nicotinic acetylcholine receptor during mammalian muscle development and denervation. Eur J Neurosci 1999;11:2856-2864.
84. Flores C, Davila-Garcia M, Ulrich Y, Kellar K. Differential regulation of neuronal nicotinic receptor binding sites following chronic nicotine administration. J Neurochem 1997; 69:2216-2219.
85. Forsayeth J, Kobrin E. Formation of oligomers containing the β3 and β4 subunits of the rat nicotinic receptor. J Neurosci 1997;17:1531-1538.
86. Froehner S. Identification of exposed and buried determinants of the membrane-bound acetylcholine receptor from Torpedo californica. Biochemistry 1981;20:4905-4915.
87. Frazier C, Buhler A, Weiner J, Dunwiddie T. Synaptic potentials mediated via αbungarotoxin-sensitive nicotinic acetylcholine receptors in rat hippocampal inter-neurons. J Neurosci 1998;18:8228-8235.
88. Fujii Y, Lindstrom J. Specificity of the T cell immune response to acetylcholine receptor in experimental autoimmune myasthenia gravis: response to subunits and synthetic peptides. J Immunol 1988;140:1830-1837.
89. Gahring L, Rogers S. Autoimmunity to glutamate receptors in Rasmussin's encephalitis: a rare finding or the tip of an iceberg? Neuroscientist 1998;4:373-379.
90. Gahring L, Rogers S, Twyman R. Autoantibodies to glutamate receptor subunit GluR2 in nonfamilial olivopontocerebellar degeneration. Neurology 1997;48:494-500.
91. Gahring L, Twyan R, Greenlee J, Rogers S. Autoantibodies to neuronal glutamate receptors in patients with paraneoplastic neurodegenerative syndrome enhance receptor activation. Mol Med 1995;1:245-253.
92. Galzi JL, Bertrand D, Devillers-Thiery A, Revah F, Bertrand S, Changeux JP. Functional significance of aromatic amino acids from three peptide loops of the α7 neuronal nicotinic receptor site investigated by site directed mutagenesis. FEBS Lett 1991;294:198-202.
93. Galzi JL, Devillers-Thiery A, Hussy N, Bertrand S, Changeux JP, Bertrand D. Mutations in the channel domain of a neuronal nicotinic receptor convert ion selectivity from cationit to anionic. Nature 1992;359:500-505.
94. Gerzanirh V, Anand R, Lindstrom J. Homomers of α8 subunits of nicotinic receptors functionally expressed in Xenopus oocytes exhibit similar channel but contrasting binding site properties compared to α7 homomers. Mol Pharmacol 1994; 45:212-220.
95. ++ modulation of human neuronal α3 nicotinic receptors. J Pharmacol Exp Ther 1998;266:311-320.
96. Geuder K, Marx A, Witzemann V, Schalke B, Toyka K, Kirchner T, Muller-Hermelink H. Pathogenic significance of fetal-type acetylcholine receptors on thymic myoid cells in myasthenia gravis. Dev Immunol 1992;2:69-75.
97. Gomez C, Gammack J. A leucine-to-phenylalanine substitution in the acetylcholine receptor ion channel in a family with the slow channel syndrome. Neurology 1995;45: 982-985.
98. Gomez C, Maselli R, Gammack J, Lasalde J, Tamamizu S, Cornblath D, Lehar M, McNamee M, Kuncl R. A β subunit mutation in the acetylcholine receptor channel gate causes severe slow channel syndrome. Ann Neurol 1996;39: 712-723.
99. Gomez C, Richman D. Anti-acetylcholine receptor antibodies directed against the αbungarotoxin-binding site induce a unique form of experimental myasthenia. Proc Nad Acad Sci USA 1983;80:4089-4093.
100. Gomez C, Richman D. Monoclonal anti-acetylcholine receptor antibodies with differing capacities to induce experimental autoimmune myasthenia gravis. J Immunol 1985;135: 234-241.
101. Gomez C, Richman D. Chronic experimental autoimmune myasthenia gravis induced by monoclonal antibody to acetylcholine receptor: biochemical and electrophysiological criteria. J Immunol 1987;139:73-76.
102. Grando S, Horton R. The keratinocyte cholinergic system with acetylcholine as an epidermal cytotransmitter. Curr Opin Dermatol 1997;4:262-268.
103. Graus Y, deBaets M, Parren P, Berrih-Aknin S, Wokke J, van Breda Vriesman P, Burton D. Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies. J Immunol 1997;158:1919-1929.
104. Gray R, Rajan A, Radcliffe K, Yakehiro M, Dani J. Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature 1996;383:713-716.
105. Groot-Kormelink P, Luyten W, Colquhoun D, Silviotti L. A reporter mutation approach shows incorporation of the "orphan" subunit β3 into a functional nicotinic receptor. J Biol Chem 1998;273:15317-15320.
106. Hara H, Hayahi K, Ohta K, Itoh N, Ohta M. Nicotinic acetylcholine receptor mRNAs in myasthenic thymuses: association with intrathymic pathogenesis of myasthenia gravis. Biochem Biophys Res Commun 1993;194:1269-1275.
107. Harcourt G, Batocchi A, Hawke S, Beeson D, Pantic N, Jacobson L, Wilcox N, Vincent A, Newsom-Davis J. Detection of a subunit isoforms in human muscle acetylcholine receptor by specific T cells from a myasthenia gravis patient. Proc R Soc Lond B 1993;254:1-6.
108. Hart I, Waters C, Vincent A, Newland C, Beeson D, Pongs O, Morris C, Newsom-Davis J. Autoantibodies detached to expressed potassium channels are implicated in neuromyotonia. Ann Neurol 1997;41:238-246.
109. Hawke S, Matsuo H, Nicolle M, Malcherek G, Melms A, Willcox N. Autoimmune T cells in myasthenia gravis; heterogeneity and potential for specific targeting. Immunol Today 1993;17:307-311.
110. Heinemann S, Bevan S, Kullberg R, Lindstrom J, Rice J. Modulation of the acetylcholine receptor by anti-receptor antibody. Proc Natl Acad Sci USA 1977;74:3090-3094.
111. Heinemann S, Merlie J, Lindstrom J. Modulation of acetylcholine receptor in rat diaphragm by anti-receptor sera. Nature 1978;274:65-68.
112. Hohlfeld R, Wekerle H. The role of the thymus in myasthenia gravis. Adv Neuroimmunol 1994;4:373-386.
113. Homann D, Dyrberg T, Peterson J, Oldstone M, von Herrath G. Insulin in oral immune "tolerance": a one-amino acid change in the B chain makes the difference. J Immunol 1999;163:1833-1838.
114. Horch H, Sargent P. Peri-synaptic surface distribution of multiple classes of nicotinic acetylcholine receptors on neurons in the chicken ciliary ganglion. J Neurosci 1995;15: 7778-7795.
115. Horton R, Manfredi A, Conti-Tronconi B. The "embryonic" γ subunit of the nicotinic acetylcholine receptor is expressed in adult extraocular muscle. Neurology 1993;43:983-986.
116. Infante A, Thompson P, Krolick K, Wall A. Determinant selection in murine experimental autoimmune myasthenia gravis. Effect of the bm12 mutation on T cell recognition of acetylcholine receptor epitopes. J Immunol 1991;146: 2977-2982.
117. Jackson M. Perfection of a synaptic receptor: kinetics and energetic of the acetylcholine receptor. Proc Natl Acad Sci USA 1989;86:2199-2203.
118. Jermy A, Beeson D, Vincent A. Pathogenic autoimmunity to affinity-purified mouse acetylcholine receptor induced without adjuvant in BALB/c mice. Eur J Immunol 1993;23: 973-976.
119. Kaminski H. Acetylcholine receptor epitopes in ocular myasthenia. Ann NY Acad Sci 1998;841:309-319.
120. Kao I, Drachman D. Thymic muscle cells bear acetylcholine receptors: possible relation to myasthenia gravis. Science 1977;195:74-75.
121. Karachunski P, Ostlie N, Okita D, Conti-Fine B. Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epilope sequences. J Clin Invest 1997;100:3027-3035.
122. Karachunski P, Ostlie N, Okita D, Garman R, Conti-Fine B. Subcutaneous administration of T-epitope sequences of the acetylcholine receptor prevents experimental myasthenia gravis. J Neuroimmunol 1999;93:108-121.
123. Karlin A, Akabas M. Toward a structural basis for the function of nicotinic acetylcholine receptors and their cousins. Neuron 1995;15:1231-1244.
124. Kaul R, Shenoy M, Goluzko E, Christadoss P. Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis. J Immunol 1994; 152:3152-3157.
125. Keesey J, Lindstrom J, Cokely A. Anti-acetylcholine receptor antibody in neonatal myasthenia gravis. N Engl J Med 1977; 296:55.
126. Keesey J, Tourtellotte W, Herrmann C, Andrews J, Lindstrom J. Acetylcholine receptor antibody in cerebrospinal fluid. Lancet 1978;1:777.
127. Keyser K, Britto L, Schoepfer R, Whiting P, Cooper J, Conroy W, Brozozowska-Prechtl A, Karten H, Lindstrom J. Three subtypes of αbungarotoxin-sensitive nicotinic acetylcholine receptors expressed in chick retina. J Neurosci 1993;13: 442-454.
128. Killen J, Lindstrom J. Specific killing of lymphocytes which cause EAMG by ricin acetylcholine receptor conjugates. J Immunol 1984;133:2549-2553.
129. Kreienkamp HJ, Maeda R, Sine S, Taylor P. Inter-subunit contacts governing assembly of the mammalian nicotinic acetylcholine receptor. Neuron 1995;14:635-644.
130. Krolick K, Yeh TM, Edlund S. Lewis rats given antibodies against denatured acetylcholine receptor become resistant to induction of experimental autoimmune myasthenia gravis. Cell Immunol 1996;172:10-20.
131. ++ permeability, conductance, and gating of human α4β2 nicotinic acetylcholine receptors. J Neurosci 1997;17:9035-9047.
132. Lambert E, Lindstrom J, Lennon V. End-plate potentials in experimental autoimmune myasthenia gravis in rats. Ann NY Acad Sci 1976;274:300-318.
133. + flux into TE671 cell line. J Neuroimmunol 1988;19:141-148.
134. Lang B, Vincent A. Autoimmunity to ion channels and other proteins in paraneoplastic disorders. Curr Opin Immunol 1996;8:865-871.
135. Lang B, Waterman S, Pinto A, Jones D, Moss F, Bool J, Brust P, Williams M, Stauderman K, Harpold M, Motomura M, Moll J, Vincent A, Newsom-Davis J. The role of autoantibodies in Lambert-Eaton myasthenic syndrome. Ann NY Acad Sci 1998;841:596-605.
136. Lee S, Sullenger B. Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies. Nature Biotechnol 1997;15:41-45.
137. Lennon V, Lindstrom J, Seybold M. Experimental autoimmune myasthenia: cellular and humoral immune responses. Ann NY Acad Sci 1976;274:283-299.
138. Lennon V, Seybold M, Lindstrom J, Cochrane C, Yulevitch R. Role of complement in pathogenesis of experimental autoimmune myasthenia gravis. J Exp Med 1978;147:973-983.
139. LeNovère N, Changeux JP. Molecular evolution of the nicotinic acetylcholine receptor: an example of a multi-gene family in excitable cells. J Mol Evol 1995;40:155-172.
140. LeNovère N, Corringer JP, Changeux JP. Improved secondary structure predictions for a nicotinic receptor subunit: incorporation of solvent accessibility and experimental data into a two-dimensional representation. Biophys J 1999;76: 2329-2345.
141. Li Z, Forester N, Vincent A. Modulation of acctylcholine receptor function in TE671 (rhabdomyosarcoma) cells by non-AChR ligands: possible relevance to seronegative myasthenia gravis. J Neuroimmunol 1995;64:179-183.
142. Liblau R, Tisch R, Bercovici N, McDevitt H. Systemic antigen in the treatment of T-cell-mediated autoimmune diseases. Immunol Today 1997;18:599-604.
143. Lindstrom J. Neuronal nicotinic acetylcholine receptors. In: Narahashi T, editor. Ion channels. New York: Plenum Press; 1996. p 377-450.
144. Lindstrom J. Purification and cloning of nicotinic acetylcholine receptors. In: Arneric S, Brioni D, editors. Neuronal nicotinic receptors: pharmacology and therapeutic opportunities. New York: John Wiley & Sons; 1999.
145. Lindstrom J. Structures of neuronal nicotinic receptors. In: dementi F, Gotti G, Fornasari D, editors. Neuronal nicotinic receptors. Berlin: Springer; 2000. p 101-162.
146. Lindstrom J. Experimental induction and treatment of myasthenia gravis. In: Engel A, editor. Myasthenia gravis and myasthenic disorders. Oxford: Oxford University Press; 1999. p 111-130.
147. Lindstrom J. Einarson B. Antigenic modulation and receptor loss in EAMG. Muscle Nerve 1979;2:173-179.
148. Lindstrom J, Einarson B, Lennon V, Seybold M. Pathological mechanisms in EAMG. I: Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental autoimmune myasthenia gravis. J Exp Med 1976;144:726-738.
149. Lindstrom J, Einarson B, Merlie D. Immunization of rats with polypeptide chains from Torpedo acetylcholine receptor causes an autoimmune response to receptors in rat muscle. Proc Natl Acad Sci USA 2978;75:769-773.
150. Lindstrom J, Engel A, Seybold M, Lennon V, Lambert E. Pathological mechanisms in EAMG. II: Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine receptor antibodies. J Exp Med 1976;144: 739-753.
151. Lindstrom J, Lambert E. Content of acetylcholine receptor and antibodies bound to receptor in myasthenia gravis, experimental autoimmune myasthenia gravis, and in Eaton-Lambert syndrome. Neurology 1978;28:130-138.
152. Lindstrom J, Peng X, Kuryatov A, Lee E, Anand R, Gerzanich V, Wang F, Wells G, Nelson M. Molecular and antigenic structure of nicotinic acetylcholine receptors. Ann NY Acad Sci 1998;841:71-86.
153. Lindstrom J, Seybold M, Lennon V. Antibody to acetylcholine receptor in myasihenia gravis: prevalence, clinical correlates, and diagnostic value. Neurology 1976;26:1054-1059.
154. Lindstrom J, Shelton GD, Fujii Y. Myasihenia gravis. Adv Immunol 1988;42:233-284.
155. Lindstrom J, Tzartos S, Gullick B. Structure and function of acetylcholine receptors studied using monoclonal antibodies. Ann NY Acad Sci 1981;377:1-19.
156. Loutrari H, Kokla A, Tzartos S. Passive transfer of experimental myasthenia acetylcholine via antigenic modulation of acetylcholine receptor. Eur J Immunol 1994;22: 2449-2452.
157. Lukas R. The effects of chronic nicotinic ligand exposure on functional activity of nicotinic acetylcholine receptors expressed by cells of the PC12 rat pheochromocytoma or the TE671/RD human clonal line. J Neurochem 1991;56: 1134-1145.
158. Ma C-G, Zhang G-X, Xiao B-G, Link J, Olsson T, Link H. Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor. J Neuroimmunol 1995;58:51-60.
159. Ma C-G, Zhang G-X, Xiao B-G, Wang Z-Y, Link J, Olsson T, Link T. Mucosal tolerance to experimental autoimmune myasthenia gravis is associated with down-regulation of AChR-specific IFN-γ-expressing Th1-like cells and upregulation of TGF-β mRNA in mononuclear cells. Ann NY Acad Sci 1996; 778:273-287.
160. Ma S-W, Zhao D-L, Yin Z-Q, Mukherjee R, Singh B, Qin H-Y, Stiller C, Jevnikar A. Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance. Nature Med 1997;3:793-796.
161. MacLennon C, Beeson D, Buijs A, Vincent A, Newsom-Davis J. Acetylcholine receptor expression in human extraocular muscles and their susceptibility to myasthenia gravis. Ann Neurol 1997;41:423-431.
162. Mamalaki A, Trakas N, Tzarlos S. Bacterial expression of single-chain Fv fragment which efficiently protects the acetylcholine receptor against antigenic modulation caused by myasthenic antibodies. Eur J Immunol 1993;23:1839-1845.
163. Marubio L, del Mar Arrayo-Jimenez M, Cordero-Erausquin M, Lena C, LeNovere N, de Kerchove d'Exaerde A, Huchet M, Damaj M, Changeux J-P. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature 1999;398:805-810.
164. Maus A, Pereira F, Karachunski P, Horton R, Navaneetham D, Macklin K, Cortes W, Albuquerque E, Conti-Fine B. Human and rodent bronchial epithelial cells express functional nicotinic acetylcholine receptors. Mol Pharmacol 1998;54: 779-788.
165. McGehee D, Role L. Physiological diversity of nicotinic acetylcoline receptors expressed by vertebrate neurons. Ann Rev Physiol 1995;57:521-546.
166. McIntosh K, Linsley P, Bocha P, Drachman D. Immunotherapy of experimental autoimmune myasthenia gravis: selective effects of CTLA 4 Ig and synergenic combination with an IL2-Diptheria toxin fusion protein. J Neuroimmunol 1998;87:136-146.
167. Meinl E, Klinkurt W, Wekerle H. The thymus in myasthenia gravis: changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat. Am J Pathol 1991;139:995-1008.
168. Melms A, Malcherik G, Gern U. Wietholter H, Schoepfer R, Lindstrom J. T
169. + thymocytes. J Neuroimmunol 1997;79:176-184.
170. Milhovilovic M, Roses A. Expression of α3, α5, and β4 neuronal acetylcholine receptor subunit transcripts in normal and myasthenia gravis thymus. J Immunol 1993;151: 6517-6524.
171. Milone M, Ohno K, Brengman J. Low affinity fast channel congenital myasthenic syndrome caused by new missense mutations in the acetylcholine receptor a subunit. Neurology 1998;50:A432-A433.
172. Milone M, Ohno K, Wang H-L. Novel slow channel syndrome due to mutation in the acetylcholine receptor α subunit with increased conductance, nanomolar affinity for acetylcholine and prolonged open durations of the AChR channel. Ann Neurol 1996;40:956.
173. Milone M, Wang H-L, Ohno K, Prince R, Fukudome T, Shen X-M, Brengman J, Griggs R, Sine S, Engel A. Mode switching kinetics produced by a naturally occurring mutation in the cytoplasmic loop of the human acetylcholine receptor ∈ subunit. Neuron 1998;20:575-588.
174. Miyazawa A, Fujiyoshi Y, Stowell M, Unwin N. Nicotinic acetylcholine receptor at 4.6 Å resolution: transverse tunnels in the channel wall. J Mol Biol 1999;288:765-786.
175. Moulian N, Wakkach A, Guyon T, Poea S, Aissaoue A, Levasseur P, Cohen-Kaminsky S, Berrih-Aknin S. Respective role of thymus and muscle in autoimmune myasthenia gravis. Ann NY Acad Sci 1998;841:397-406.
176. Nachamkin I, Alos B, Ho T. Campylobacter species and Guillain-Barre syndrome. Clin Microbiol Rev 1998;11:555-567.
177. Nagel A, Engel A, Lang B, Newsom-Davis J, Fukuoka T. Lambert-Eaton myasthenia syndrome IgG depletes pre-synaptic membrane active zone particles by antigenic modulation. Ann Neurol 1988;24:552-558.
178. Nagvekar N, Corlett L, Jocobson L, Matsuo H, Chakley R, Driscoll P, Deshpande S, Spack E, Willcox N. Scanning a DRB 3*0110 (DR52a)-restricted epitope cross-presented by DR3: overlapping natural and artificial determinants in the human acetylcholine receptor. J Immunol 1999;162: 4079-4087.
179. Nelson S, Conti-Troconi B. Adult thymuses express an embryonic nicotinic acetylcholine receptor-like protein. J Neuroimmunol 1990;29:81-92.
180. Nelson M, Kuryatov S, Lindstrom J. Host cell effects on functional properties of human α4β2 nicotinic AChRs. Neurosci Soc Mtg Abstr 1999;684:15.
181. Newland C, Beeson D, Vincent A, Newsom-Davis J. Functional and non-functional isoforms of the human muscle acetylcholine receptor. J Physiol 1995;489:767-778.
182. Newsom-Davis J, Willcox N, Schluep M, Harcourt G, Vincent A, Mossman S, Wray D, Burges J. Immunulogical heterogeneity and cellular mechanisms in myasthenia gravis. Ann NY Acad Sci 1987;505:12-26.
183. Nichols P, Croxen R, Vincent A, Rulter R, Hutchinson M, Newsom-Davis J, Beeson D. Mutation of the acetylcholine receptor ∈ subunit promoter in congenital myasthenia syndrome. Ann Neurol 1999;45:439-443.
184. Noda M, Furutani Y, Takahashi M, Toyosato T, Tanabe T, Shimizu S, Kikyotani S, Kayano T, Hirose T, Inayama S, Numa S. Cloning and sequence analysis of calf cDNA and human genomic DNA encoding alpha subunit precursor of muscle acetylcholine receptor. Nature 1983;305:818-823.
185. Ohno K, Anlar B, Engel A. Congenital myasthenic syndrome caused by a mutation in the Ets-binding site of the promoter region of the acetylcholine receptor ∈ subunit gene. Neuromusc Disord 1999;9:131-135.
186. Ohno K, Anlar B, Ozdirim E, Brengman J, DeBleecker J, Engel A. Myasthenic syndromes in Turkish kinships due to mutations in the acetylcholine receptor. Ann Neurol 1998; 44:234-241.
187. Ohno K, Brengman J, Tsujino A, Engel A. Human endplate acetylcholinesterase deficiency caused by mutations in the collagen-like tail subunit (ColQ) of the asymmetric enzyme. Proc Natl Acad Sci USA 1998;95:9654-9659.
188. Ohno K, Hutchinson D, Milone M, Brengman J, Bouzat C, Sine S, Engel A. Congenital myasthenia syndrome caused by prolonged acetylcholine receptor channel openings due to a mutation in the M2 domain of the ε subunit. Proc Natl Acad Sci USA 1995;92:758-762.
189. Ohno K, Quiram P, Milone M, Wang H-L, Harpoer M, Preitt J, Brengman J, Pao L, Fischbeck K, Crawford T, Sine S, Engel A. Congenital myasthenic syndromes due to heteroallelic nonsense/missense mutations in the acetylcholine receptor ∈ subunit gene: identification and functional characterization of six new mutation. Hum Mol Gen 1997;6:753-766.
190. Ohno K, Wang H-L, Milone M, Bren N, Brengman J, Nakano S, Ouiram P, Pritt J, Sine S, Engel A. Congenital myasthenic syndrome caused by decreased agonist binding affinity due to a mutation in the acetylcholine receptor ε subunit. Neuron 1996;17:157-170.
191. Okamura S, McIntosh K, Drachman D. Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis. Ann Neurol 1994;36:704-713.
192. Olale F, Gerzanich V, Kuryatov A, Wang F, Lindstrom J. Chronic nicotine exposure differentially affects the function of human α3, α4, and α7 neuronal nicotinic receptor subtypes. J Pharmacol Exp Ther 1997;283:675-683.
193. Olsberg C, Mikiten T, Krolick K. Selective in vitro inhibition of an antibody response to purified acetylcholine receptor by using antigen-ricin A chain immunotoxin. J Immunol 1985;135:3062-3067.
194. Orr-Urtreger A, Göldner F, Saeki M, Lorenzo I, Goldberg L, DeBiasi M, Dani J, Patrick J, Beaudet A. Mice deficient in the α7 neuronal nicotinic acetylcholine receptor lack αbungarotoxin binding sites and hippocampal fast nicotinic currents. J Neurosci 1997;17:9165-9171.
195. Oshima M, Ashizawa T, Pollack M, Atassi Z. Autoimmune T cell recognition of human acetylcholine receptor: the sites of T cell recognition in myasthenia gravis on the extracellular part of the a subunit. Eur J Immunol 1990;20:2563-2569.
196. Oshima M, Pachner A, Atassi M. Profile of the regions of acetylcholine receptor α chain recognized by T-lymphocytes and by antibodies in EAMd-susceptible and non-susceptible mouse strains after different periods of immunization with the receptor. Mol Immunol 1994;31:833-843.
197. v antibody fragment against the main immunogenic region of the acetylcholine receptor. J Neuroimmunol 1999;94:182-195.
198. Papke R, Bencherif M, Lippiello P. An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective for the α7 subtype. Neurosci Lett 1996;213:201-204.
199. Papke R, Thinschmidt J. The correction of α7 nicotinic acetylcholine receptor concentration-response relationships in Xenopus oocytes. Neurosci Lett 1998;256:163-166.
200. Patrick J, Lindstrom J. Autoimmune response to acetylcholine receptor. Science 1973;180:871-872.
201. Patrick J, Lindstrom J, Culp B, McMillan J. Studies on purified eel acetylcholine receptor and anti-acetylcholine receptor antibody. Proc Natl Acad Sci USA 1973;70:3334-4448.
202. Paylor R, Nguyen M, Crawley J, Patrick J, Beaudet A, Orr-Urtreger A. α7 nicotinic receptor subunits are not necessary for hippocampal-dependent learning or sensorimotor gating: a behavioral characterization of Acra 7-dificient mice. Learn Memory 1998;5:302-316.
203. Peng X, Anand R, Whiting P, Lindstrom J. Nicotine-induced upregulation of neuronal nicotinic receptors results from a decrease in the rate of turnover. Mol Pharmacol 1994;46: 523-530.
204. Peng X, Gerzanich V, Anand R, Wang F, Lindstrom J. Chronic nicotine treatment upregulates α3 and α7 acetylcholine receptor subtypes expressed by the human neuroblastoma cell line SH-SY5Y. Mol Pharmacol 1997;51: 776-784.
205. Penn A, Low B, Jaffe I, Luo L, Jacques J. Drug-induced autoimmune myasthenia gravis. Ann NY Acad Sci 1998;841: 433-447.
206. Picciotto M, Zoli M, Lena C, Besis A, Lallemand Y, Le Novére N, Vincent P, Pich M, Brület P, Changeux J-P. Abnormal avoidance learning in mice lacking functional high affinity nicotine receptor in the brain. Nature 1995;374:65-67.
207. Picciotto M, Zoli M, Rimondini R, Léna C, Marubio L, Pich E, Fuxe K, Changeux J-P. Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature 1998;391:173-177.
208. Protti M, Manfredi A, Horton R, Bellone M, Conti-Tronconi B. Myasthenia gravis: recognition of a human autoantigen at the molecular level. Immunol Today 1993;14:363-368.
209. Raghel S, Lisak R. Immune regulation and myasthenia gravis. Ann NY Acad Sci 1998;841:211-224.
210. Ramirez-Latorre J, Yu C, Qu C, Perin F, Karlin A, Role L. Functional contributions of α5 subunit to neuronal acetylcholine receptor channels. Nature 1996:380:347-351.
211. Richman D. Myasthenia gravis and related diseases. Ann NY Acad Sci 1998;841.
212. Riemersma S, Vincent A, Beeson D, Newland C, Hawke S, Vernet-der Garabedian B, Eymard B, Newsom-Davis J. Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function. J Clin Invest 1996:2358-2363.
213. Rogers S, Andrews J, Gahring L, Whisemand T, Caulay K, Crain B, Hughes T, Heinmann S, McNamara J. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 1994;265:648-651.
214. Romano S, Corriveau R, Srhwarz R, Berg D. Expression of the nicotinic receptor α7 gene in tendon and periosteum during early development. J Neurochem 1997;68:640-648.
215. Romano S, Pugh P, McIntosh J, Berg D. Neuronal-type acetylcholine receptors and regulation of α7 gene expression in vertebrate skeletal muscle. J Neurobiol 1997;32:69-80.
216. Roy K, Mao HQ, Huang SK. Leong K. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1999:;5:387-391.
217. Russell A, Lindstrom J. Penicillamine induced myasthenia gravis associated with antibodies lo the acetylcholine receptor. Neurology 1978;28:847-849.
218. Saedi MS, Anand R, Conroy WG, Lindstrom J. Determination of amino acids critical to the main immunogenic region of intact acetylcholine receptors by in vitro mutagenesis. FEBS Lett 1990;267:55-59.
219. Sahashi K, Engel AG, Lambert E, Howard F. Ultrastructural localization of the terminal and lylic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J Neuropathol Exp Neurol 1980;39:160-172.
220. Sahashi K, Engel AG, Lindstrom J, Lambert EH, Lennon V. Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis. J Neuropathol Exp Neurol 1978;37:212-223.
221. Sanes J, Lichtman J. Development of the vertebrate neuromuscular junction. Annu Rev Neurosci 1999;22:389-442.
222. Sargent P, Hedges B, Tsavaler L, Clemmons L, Tzartos S, Lindstrom J. The structure and transmembrane nature of the acetylcholine receptor in amphibian skeletal muscles revealed by crossreacting monoclonal antibodies. J Cell Biol 1984;98:609-618.
223. Scadding G, Calder L, Vincent A, Prior C, Wray D. Newsom-Davis J. Anti-acetylcholine receptor induced in mice by syngeneic receptor without adjuvants. Immunology 1986;58: 151-155.
224. Schoenbeck S, Padberg F, Hohlfeld R, Wekerle H. Transplantation of thymic autoimmune microenvironment to SCID mice: a new model of mvasthenia gravis. J Clin Invest 1992;90:245-250.
225. Schluep M, Willcox N, Vincent A, Dhoot G, Newsom-Davis J. Acetylcholine receptors in human thymic myoid cells in situ: an immunohistological study. Ann Neurol 1987;22:212-222.
226. Seguela P, Wadiche J, Dinelly-Miller K, Dani J, Patrick J. Molecular cloning functional properties, and distribution of rat brain α7: a nicotinic cation channel highly permeable to calcium. J Neurosci 1993;13:596-604.
227. Sekhon H, Jia Y, Raab R, Kuryalov A, Pankow J, Whitsett J, Lindstrom J, Spindel E. Prenatal nicotine exposure increases α7 nicotinic acetylcholine receptor expression in pulmonary cells and alters fetal lung development in monkeys. J Clin Invest 1999;103:637-647.
228. Seybold M, Lindstrom J. Patterns of acetylcholine receptor antibody fluctuation in myasthenia gravis. Ann NY Acad Sci 1981;377:292-306.
229. Shelton GD, Fujii Y, Knogge W, Lindstrom J. Suppression of the antibody response in experimental autoimmune myasthenia gravis by daunomycin-acetylcholine receptor conjugates in vitro and in vivo Ann NY Acad Sci 1988;540:530-533.
230. Shelton GD, Cardinet GH III, Lindstrom JM. Canine and human mvasthenia gravis autoantibodies recognize similar regions on the acetylcholine receptor. Neurology 1988;38: 1417-1424.
231. Shelton G, Schule A, Kass P. Risk factors for acquired myasthenia gravis in dogs: 1,154 cases (1991-1995). J Am Vet Med Assoc 1997;211:1428-1431.
232. + cell deficiency on experimental autoimmune mvasthenia gravis in Lewis rats. J Immunol 1994;153:5330-5335.
233. Shenoy M, Oshima M, Alassi M, Christadoss P. Suppression of experimental autoimmune mvasthenia gravis by epitope-specific neonatal tolerance to synthetic region α 146-162 of acetylcholine receptor. Clin Immunol Immunopathol 1993; 66:230-238.
234. Shi FD, Li H, Wang H, Bai X, Van der Meide P, Link H, Ljunggren HG. Mechanisms of nasal tolerance induction in experimental autoimmune myasthenia gravis: identification of regulatory cells. J Immunol 1999;162:5757-5763.
235. Shoop R, Martone M, Yamada N, Ellisman M, Berg D. Neuronal acetylcholine receptors with α7 subunit are concentrated on somatic spines for synaptic signaling in embryonic chick ciliary ganglia. J Neurosci 1999;19:692-704.
236. Sine S, Bren N, Quiram P. Molecular dissection of subunit interfaces in the nicotinic acetylcholine receptor. J Physiol 1998;92:101-105.
237. Sine S, Ohno K, Borezat C, Auerbach A, Milone M, Pritt J, Engel A. Mutation of the acetylcholine receptor α subunit causes a slow channel myasthenic syndrome by enhancing agonist binding affinity. Neuron 1995;15:229-239.
238. Sophianos D, Tzartos S. Fab fragments of monoclonal antibodies protect the human acetylcholine receptor agonist degradation caused by myasthenic sera. J Autoimmunol 1989;2:779-789.
239. Souronoujon M, Cannon S, Fuchs S. Modulation of anti-acetylcholine receptor antibody specificities and of experimental autoimmune mvasthenia gravis by synthetic peptides. Immunol Lett 1992;34:19-26.
240. Steinlein O, Mulley J, Propping P, Wallace R, Philips H, Sutherland G, Scheffer I, Berkovic S. A missense mutation in the neuronal nicotinic acetylcholine receptor α4 subimit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 1995;11:201-203.
241. Steinlein O, Magnussan A, Sloodt J, Bertrand S, Weiland S, Berkovic S, Nakken K, Propping P, Bertrand D. An insertion mutation of the CHRNA4 gene in a family with autosomal dominant nocturnal frontal lobe epilepsy. Hum Mol Gen 1997;6:943-947.
242. Strobel S, Mowat A. Immune responses to dietary antigens: oral tolerance. Immunol Today 1998;19:173-181.
243. Thomas J, Willcox N, Newsom-Davis J. Immunohistological studies of the thymus in myasthenia gravis. Correlation with clinical state and thymocyte culture responses. J Neuroimmunol 1982;98:2358-2363.
244. Toyka K, Drachman D, Pestronk A, Kao I. Myasthenia gravis: passive transfer from man to mouse. Science 1975;190: 397-399.
245. Toyka KV, Birmberger KL, Anzil AP, Schlegel C, Besinger V, Struppler A. Myasthenia gravis: further electrophysiological and ultrastructural analysis of transmission failure in the mouse passive transfer model. J Neurol Neurosurg Psychiatry 1978;41:746-753.
246. Treinen M, Chalfie M. A mutated acetylcholine receptor subunit causes neuronal degeneration in C. elegans. Neuron 1995;14:871-877.
247. Tsantili P, Tzartos S, Mamalaki A. High affinity single chain Fv antibody fragments protecting the human nicotinic acetylcholine receptor. J Neuroimmunol 1999;94:15-27.
248. Twyman R, Gahring L, Spiess J, Rogers S. Glutamate receptor antibodies activate a subset of receptors and reveal an agonist binding site. Neuron 1995;14:755-762.
249. Tzartos S, Barkas T, Cung M, Mamalaki A, Marraud M, Papanastasiou D, Sakarellos C, Sakarellos-Daitsiotis M, Tsantili P. Tsikaris V. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol Rev 1998;163:89-120.
250. Tzartos S, Hochschwender S, Vasquez P, Lindstrom J. Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor. J Nenroimmunol 1987;15: 185-194.
251. Tzartos S, Langeberg L, Hochschwender S, Swanson L, Lindstrom J. Characteristics of monoclonal antibodies to denatured Torpedo and to native calf acetylcholine receptors: species, subimit and region specificity. J Neuroimmunol 1986; 10:235-253.
252. Tzartos S, Lindstrom J. Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits. Proc Natl Acad Sci USA 1980;77:755-759.
253. Tzartos S, Seybold M, Lindstrom J. Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc Natl Acad Sci USA 1982;79:188-192.
254. Vernet-der Garabedian B, Lacokova M, Eymard B, Morel E, Faltin M, Zajac J, Sadovsky O, Dommergues M, Tripoli P, Bach JF. Association of neonatal myasthenia gravis with antibodies against the fetal acetylcholine receptor. J Clin Invest 1994;94:555-559.
255. Vernino S, Adamski J, Kryzer T, Fealey R, Lennon V. Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer related syndromes. Neurology 1998;50:1806-1813.
256. Vetter D, Liberman M, Mann J, Barhanin J, Boulter J, Brown M, Saffiote-Kolman J, Heinemann S, Elgoyhen A. Role of α9 nicotinic ACh receptor subunits in the development and function of cochlear efferent innervation. Neuron 1999;23: 93-103.
257. Vincent A, Lang B, Newsom-Davis J. Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder. Trends Neurosci 1989;12:496-502.
258. Vincent A, Newland C, Brueton L, Beeson D, Riemersma S, Huson S, Newsom-Davis J. Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen. Lancet 1995;346:24-25.
259. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody characteristics in myasthenia gravis. II. Patients with penicillamine-induced myasthenia or idiopathic myasthenia of recent onset. Clin Exp Immunol 1982;49:266-272.
260. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic lest lor myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985;48:1246-1252.
261. Vincent A, Willcox K, Hill M, Curnow J, MacLennon C, Beeson D. Determinant spreading and immune responses to acetylcholine receptors in myasthenia gravis. Immunol Rev 1998;164:157-168.
262. Voltz R, Kamm C, Padberg F, Malotka J, Kerschensteiner M, Spuler S, Tzartos S, Dornmair K. Highly purified oligo-His tagged human recombinant α1-AChR is immunogenic in vivo and suitable for T cell stimulation in vitro in experimental and human myasthenia gravis. J Neuroimmunol 1997;80: 131-136.
263. Wakkach A, Gryon T, Bruand C, Tzartos S, Cohen-Kaminsky S, Berrih-Aknin S. Expression of acetylcholine receptor genes in human thymic epithelial cells. Implications for myasthenia gravis. J Immunol 1996;157:3752-3760.
264. Wan K, Lindstrom J. Effects of monoclonal antibodies on the function of acetylcholine receptors purified from torpedo californica and reconstituted into vesicles. Biochemistry 1985; 24:1212-1221.
265. Wang F, Gerzanich V, Wells G, Anand R, Peng X, Keyser K, Lindstrom J. Assembly of human neuronal nicotinic receptor α5 subunits with α3, β2, and β4 subunits. J Biol Chem 1996;271:7656-17665.
266. Wang F, Nelson M, Kuryatov A, Keyser K, Lindstrom J. Chronic nicotine treatment up-regulates human α3 β2 but not α3 β4 acetylcholine receptors stably transfected in human embryonic kidney cells. J Biol Chem 1998;273: 28721-28732.
267. Wang H-L, Aurbach A, Bren N, Ohno K, Engel A, Sine S. Mutation in the M1 domain of the acetylcholine receptor α subunit decreases the rate of agonist dissociation. J Gen Physiol 1997;109:757-766.
268. Wang Z-Y, Huang J, Olsson T, He B, Link H. B cell responses to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis. J Neurol Sci 1995;128:167-174.
269. + cells. Neurology 1999;52: 484-497.
270. Wang Z-Y, Link H, Ljungdahl A, Hojeberg B, Link J, He B, Qiao J, Melms A, Olsson T. Induction of interferon-γ, interleukin-4, and transforming growth factor-β in rats orally tolerized against experimental autoimmune myasthenia gravis. Cell Immunol 1994;157:353-368.
271. Wang ZY, Okita D, Howard J, Conti-Fine B. Th1 epitope repertoire on the a subunit of human muscle acetylcholine receptor in myasthenia gravis. Neurology 1997;48: 1643-1653.
272. Wang Z-Y, Qiao J, Link H. Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. J Neuroimmunol 1993;44:209-214.
273. Wang Z-Y, Qiao J, Melms A, Link H. T cell reactivity to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis. Cell Immunol 1993; 152:394-404.
274. Weiland S, Weitzmann V, Villarroel A, Propping P, Steinlein O. An amino acid exchange in the second transmembrane segment of a neuronal nicotinic receptor causes partial epilepsy by altering its desensitization kinetics. FEBS Lett 1996; 398:91-96.
275. Weinberg C, Hall Z. Antibodies from patients with myasthenia gravis recognize determinants unique to extrajunctional acetylcholine receptors. Proc Natl Acad Sci USA 1979;76: 504-508.
276. Weiner H. Oral tolerance for the treatment of autoimmune diseases. Annu Rev Med 1997;48:341-351.
277. Whiting P, Cooper J, Lindstrom J. Antibodies in sera from patients with myasthenia gravis do not bind to acetylcholine receptors from human brain. J Neuroimmunol 1987;16: 205-213.
278. Whiting P, Lindstrom J. Purification and characterization of a nicotinic: acetylcholine receptor from chick brain. Biochemistry 1986:25:2082-2093.
279. Whiting P, Lindstrom J. Characterization of bovine and human neuronal nicotinic acetylcholine receptors using monoclonal antibodies. J Neurosci 1988;8:3395-3404.
280. Whitney K, McNamara J. Antoimmunity and neurological disease: antibody modulation of synaptic transmission. Annu Rev Neurosd 1999;22:175-195.
281. Willcox H. Thymic tumors with myasthenia gravis or bone marrow dyscrasias. In: Peckham M, editor. Oxford textbook of oncology. Oxford: Oxford University Press; 1995. p 1562-1568.
282. Wilson G, Karlin A. The location of the gate of the acetylcholine receptor channel. Neuron 1998;20:1269-1281.
283. Wintzen A, Plomp J, Molenaar P, Dijk G, van Kempen G, Vos R, Wokke J, Vincent A. Acquired slow-channel syndrome: a form of myasthenia gravis with prolonged open lime of the acetylcholine receptor channel. Ann Neurol 1998;44: 657-664.
284. Wonnacott S. Pre-synaptic nicotinic ACh receptors. Trends Neurosd 1997;20:92-98.
285. Wu B, Deng C, Goluszko E, Christadoss P. Tolerance to a dominant T cell epitope in the acetylcholine receptor molecule induces epitope spread and suppresses murine myasthenia gravis. J Immunol 1997;159:3016-3023.
286. Wu B, Shenoy M, Christadoss P. T cell receptor gene regulation of experimental autoimmune myasthenia gravis. Adv Neuroimmunol 1994;4:433-435.
287. Xiao B-G, Link H. Mucosal tolerance: a two edged sword to prevent and treat autoimmune disease. Clin Immunol Immunopathol 1997;85:119-128.
288. Xu W, Gelber S, Orr-Urtreger A, Armstrong D, Lewis R, Ott CN, Patrick J, Role L, DeBiasi M, Beaudet A. Magacystis, mydriasis, and ion channel defect in mice lacking the α3 neuronal nicotinic receptor. Proc Natl Acad Sci USA 1999; 96:5746-5751.
289. Xu W, Orr-Urtreger A, Nigro F, Gelber S, Sutcliffe C, Armstrong D, Patrick J, Role L, Beaudet A, DeBiasi M. Multiorgan autonomic dysfunction in mice lacking the β2 and the β4 subunits of neuronal nicotinic acetylcholine receptors. J Neurosci 1999;19:9298-9305.
290. Yeh T-M, Krolick K. T cells reactive with a small synthetic peptide of the acetylcholine receptor can provide help tor a clonotypically heterogeneous antibody response and subsequently impaired muscle function. J Immunol 1990;144: 1654-1660.
291. Yoon J-W. Yoon C-S, Lim H-W, Huang Q, Kang Y, Pyun K, Hirasawa K, Sherwin R, Jun H-S. Control autoimmune diabetes in NOD mice by GAD expression or suppression in β cells. Science 1999;284:1183-1187.
292. Younger D, Worrall B, Penn A. Myasthenia gravis: historical perspective and overview. Neurology 1997;48(suppl):S1-S7.
293. + T cells suppresses the development of experimental autoimmune myasthenia gravis in Lewis rats. Eur J Immunol 1995;25:1191-1198.
294. Zhang G-X, Shi F-D, Zhu J, Xiao B-G, Levi M, Wahren B, Yu LY, Link H. Synthetic peptides fail to induce nasal tolerance to experimental autoimmune myasthenia gravis. J Neuroimmunol 1998;85:96-101.
295. + T cells are essential to induce experimental autoimmune myasthenia gravis. J Exp Med 1996;184:349-356.
296. Zhang H, Karlin A. Identification of acetylcholine receptor channel-lining residues in the M1 segment of the β-subunit. Biochemistry 1997;36:15856-15864.
297. Zhang H, Karlin A. Contribution of the β subunit M2 segment to the ion-conducting pathway of the acetylcholine receptor. Biochemistry 1998;37:7952-7964.
298. Zheng Y, Wheatly L, Liu T, Levinson A. Acetylcholine receptor α subunit mRNA expression in human thymus: augmented expression in myasthenia gravis and upregulation by interferon-γ. Clin Immunol 1999;91:170-177.
299. Zhou M, Engel A, Auerbach A. Serum choline activates mutant acetylcholine receptors that cause slow channel myasthenic syndromes. Proc Natl Acad Sci USA 1999;96: 10466-10471.
300. Zoda TE, Krolick KA. Antigen presentation and T cell specificity repertoire in determining responsiveness to an epitope important in experimental autoimmune myasthenia gravis. J Neuroimmunol 1993;43:131-138.
301. Zoli M, Picciotto M, Ferrari R, Coccbhi D, Changeux JP. Increased neurodegeneration during aging in mice lacking high-affinity nicotine receptors. EMBO J 1999;18:1235-1244.